14 Schizophrenia Clinical Trials in Garden Grove, CA (2026)

Q: How do I join a clinical trial in Garden Grove?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Garden Grove research site will contact you.

Recruiting Schizophrenia Studies in Garden Grove

NCT05184335Recruiting

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg o...

Garden Grove, CAPHASE3690 participantsReviva Pharmaceuticals

View Study Details

NCT07114874Recruiting

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia....

Garden Grove, CAPHASE3600 participantsNeurocrine Biosciences

View Study Details

NCT07227818Recruiting

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with N...

Garden Grove, CAPHASE3560 participantsNeurocrine Biosciences

View Study Details

NCT06894212Recruiting

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...

Garden Grove, CAPHASE3522 participantsOtsuka Pharmaceutical Development & Commercialization, Inc.

View Study Details

NCT07459647Recruiting

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an ...

Garden Grove, CAPHASE2500 participantsMapLight Therapeutics

View Study Details

NCT07363577Recruiting

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult pati...

Garden Grove, CAPHASE3456 participantsLB Pharmaceuticals Inc.

View Study Details

NCT07410507Recruiting

A Study of Brenipatide in Adult Participants With Schizophrenia

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is d...

Garden Grove, CAPHASE2450 participantsEli Lilly and Company

View Study Details

NCT07565428Recruiting

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study t...

Garden Grove, CAPHASE3380 participantsMinerva Neurosciences

View Study Details

NCT06229210Recruiting

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder....

Garden Grove, CAPHASE3300 participantsIntra-Cellular Therapies, Inc.

View Study Details

NCT07105098Recruiting

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults....

Garden Grove, CAPHASE3284 participantsNeurocrine Biosciences

View Study Details

NCT07145918Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess advers...

Garden Grove, CAPHASE2268 participantsAbbVie

View Study Details

NCT06502964Recruiting

Study of ALTO-101 in Patients With Schizophrenia

This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers an...

Garden Grove, CAPHASE282 participantsAlto Neuroscience

View Study Details

NCT07615426Recruiting

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant i...

Garden Grove, CAPHASE164 participantsJanssen Research & Development, LLC

View Study Details

NCT07221877Recruiting

A Study to Evaluate the Effect of KarXT on Urological Safety

The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia....

Garden Grove, CAPHASE460 participantsBristol-Myers Squibb

View Study Details

About Schizophrenia Clinical Trials in Garden Grove

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 14 schizophrenia clinical trials recruiting participants in Garden Grove, CA. These studies are seeking a combined 5,216 participants. Research is being sponsored by Reviva Pharmaceuticals, Neurocrine Biosciences, Otsuka Pharmaceutical Development & Commercialization, Inc. and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Schizophrenia Clinical Trials in Garden Grove — FAQ

Are there schizophrenia clinical trials in Garden Grove?

Yes, there are 14 schizophrenia clinical trials currently recruiting in Garden Grove, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Garden Grove?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Garden Grove research site will contact you about next steps.

Are clinical trials in Garden Grove free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Garden Grove studies also compensate for your time and travel.

What schizophrenia treatments are being tested?

The 14 active trials in Garden Grove are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.

Data updated September 5, 2026 from ClinicalTrials.gov